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The effects of a tea tree oil-containing gel on plaque and
chronic gingivitis
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Abstract
Background: This clinical study assessed the effects
of topically applied tea tree oil (TTO)-containing gel
on dental plaque and chronic gingivitis.
Methods: This was a double-blind, longitudinal,
non-crossover study in 49 medically fit non-smokers
(24 males and 25 females) aged 18-60 years with
severe chronic gingivitis. Subjects were randomly
assigned to three groups and given either TTO-gel
(2.5 per cent), chlorhexidine (CHX) gel (0.2 per
cent), or a placebo gel to apply with a toothbrush
twice daily. Treatment effects were assessed using the
Gingival Index (GI), Papillary Bleeding Index (PBI)
and plaque staining score (PSS) at four and eight
weeks.
Results: No adverse reactions to any of the gels were
reported. The data were separated into subsets by
tooth (anterior and posterior) and tooth surface
(buccal and lingual). The TTO group had significant
reduction in PBI and GI scores. However, TTO did
not reduce plaque scores, which tended to increase
over the latter weeks of the study period.
Conclusion: Although further studies are required,
the anti-inflammatory properties of TTO-containing
gel applied topically to inflamed gingival tissues may
prove to be a useful non-toxic adjunct to
chemotherapeutic periodontal therapy.
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there is very little literature regarding the periodontal
effects of TTO; such products do not have to undergo
the strict evaluation procedures required by federal
bodies for conventional products.
The main active ingredients of TTO are 1,8-cineole
and terpinen-4-ol; it also contains many more
components whose biological properties have not been
thoroughly researched. These components are also
found in other common essential oils, e.g., eucalyptus
and fennel oil. 1,8-cineole has anti-inflammatory
properties,2-4 and is able to penetrate human skin.5
Terpinen-4-ol has similar anti-inflammatory activities
as 1,8-cineol6,7 but also has anti-bacterial activity.8-12
TTO shares a similar range of antimicrobial activity
with chlorhexidine (CHX), although their mechanisms
of action differ.9,12-18 They both have antibacterial,
antiviral and antifungal properties. TTO has the
potential to be a therapeutic agent in chronic gingivitis
and periodontitis, conditions that have both bacterial
and inflammatory components.
The aim of this study was to determine the effect of
a TTO-containing gel used twice daily on existing
gingival inflammation and plaque quantity in
unsupervised, periodontally untreated subjects.
MATERIAL AND METHODS
The University of Adelaide’s Human Research Ethics
Committee gave ethical approval for the study.
Informed consent was obtained from all subjects. Male
and female non-smokers aged between 18-60 years
with moderate to severe plaque-induced gingivitis (GI
score of 2-3 in a minimum of one tooth in each
quadrant) were recruited. The subjects had a minimum
of 20 teeth and did not have diabetes, hepatic or kidney
disease, rheumatoid arthritis, were not pregnant or
lactating, had not received periodontal therapy in the
last six months and had no known allergies to TTO.
Other exclusion criteria included individuals taking
steroids, NSAIDs, dilantin, antibiotics for at least seven
days in the last six months and subjects requiring
antibiotic cover for dental treatment.
The study design was double-blind, longitudinal
non-crossover, using three groups; a test group, TTO
INTRODUCTION
Tea tree oil (TTO) is derived from the paper bark tea
tree, which is part of the family Myrtaceae; it belongs
to two genera, Leptospermum and Melaleuca.
Australian Aborigines have used plant-derived
medications including TTO for tens of thousands of
years. These preparations are used both internally and
externally for the alleviation of pain and the promotion
of healing.1 TTO is used by Aborigines to treat
abrasions, cuts, colds and influenza. TTO is now used
around the world in many cosmetic, medicinal and
dental products (e.g., ‘natural’ toothpastes). However,
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(2.5 per cent TTO-containing gel), a positive control
group, CHX (0.2 per cent chlorhexidine gel (Periogard,
Colgate, NSW, Australia)), and a negative control
group, PLB (placebo gel identical to the test agent but
not containing TTO). The duration of the study was
eight weeks with the following indices measured at 0,
four and eight weeks: Gingival Index (GI),19 Papillary
Bleeding Index (PBI) and Plaque Surface Score (PSS).
The plaque scoring system (PSS) was a modification by
Turesky of the plaque index;20 disclosing solution
containing 1 per cent w/v erythrosine (Disclogel,
Colgate, NSW, Australia) was applied to the teeth.
At their first visit, subjects were instructed to apply
the gel along the entire length of the supplied
toothbrushes. Detailed instructions on the use of the
gels were given to subjects in the form of a two page
pamphlet. The gel was then to be used as a dentrifice
making sure that it made contact with the gingival
tissues adjacent to the teeth for a minimum of two
minutes twice daily. No rinsing, eating or drinking was
allowed for 30 minutes after gel application. Subjects
were asked to refrain from using proprietary
toothpastes and mouthwashes during the study and no
auxiliary cleaning aids were allowed to be used during
the course of the study. The gels were randomly
distributed to the subjects; neither researcher nor
subjects were aware of the contents of the tubes
distributed.
Repeat examinations were carried out on five
subjects between the ages of 26-63 years measuring GI,
PBI, PSS at four sites around each tooth (one day
between examinations) to establish intra-examiner
error. The same examination procedures were used as
in the subsequent study.
Data analyses
Statistical analyses of the data were carried out using
a computer software programme (SPSS version 10.05,
Chicago, USA). ANOVA tests were used to identify
significant differences between the means of the study
groups. Scheffe’s test was used to determine statistically
significant variations between the means of each group.
Finally, paired t tests were used to assess the
significance of changes within each group between time
periods 0-4, 4-8 and 0-8 weeks. The data for each
subject were added, averaged and weighted depending
on the number of teeth used from the subject.
RESULTS
Profile of the study population
Fifty-eight subjects were recruited, but due to several
dropouts during the study, data from nine subjects were
not used in the final analyses. The 49 subjects consisted
of 25 males and 24 females. Table 1 shows the age and
gender distribution; there were no statistically
significant age or gender differences between the
groups (Pearson chi-square, p=0.772 and p=0.889
respectively).
Statistical analysis showed that intra-examiner error
was within acceptable limits.
There were no reports of adverse reactions to any of
the gels. Few significant differences between the three
groups were found in regards to mean changes in GI,
PSS and PBI scores. When data for all teeth and surfaces
were included in the analyses, most changes in all three
groups occurred during the first four weeks of the
study. When the data were separated into anterior/
posterior and buccal/lingual surfaces, ANOVA tests of
PBI showed that the subjects using the TTO-containing
gel had statistically significant means changes compared
to the positive and negative controls in posterior teeth
and buccal surface data sets. ANOVA tests were also
determined for the differences between groups in terms
of improvement, i.e., lower scores in weeks four and
eight compared to baseline, for PBI, GI and PSS data.
See Fig 1 and 2 for a summary of PBI and GI data.
The TTO group showed the most number of
improvements in PBI in data sets for all teeth and
surfaces (grouped data), buccal, anterior and posterior
teeth. All but one of the data sets (anterior teeth data
set) was statistically significant. The buccal data
showed the largest improvement in PBI scores. The
TTO group had the greatest number of time periods
with the most improvements (9), next was the CHX
group (4) and then the PLB group (1).
The CHX group had the greatest number of time
periods with the most improvements in GI (7), next was
the TTO group (6) and then the PLB group (5). The
TTO group had the greatest number of improved sites
in GI. Overall the differences between the groups were
not great, indicated by the lack of statistically
significant results.
There were no statistically significant differences in
PSS between the groups. The TTO group consistently
had the lowest number of sites that improved for all
time periods. The CHX group generally had more
improvement in PSS than the other groups. For
example, the CHX group had more time periods with
the most improvements (11), next was the PLB group
(4) and then the TTO group (1).
Mean changes within groups
Paired t tests showed that changes in GI and PBI
were statistically significant (see Fig 1 and 2). The
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Table 1. Distribution in treatment groups of subjects by age and gender
Group Female Male n Mean age SD LB 95% CI HB 95% CI Min age Max age
PLB 7 8 15 46.53 7.90 42.16 50.91 32 61
CHX 10 8 18 44.89 11.62 39.11 50.67 26 63
TTO 7 9 16 45.50 8.84 40.79 50.21 30 62
Total 24 25 49 45.59 9.53 42.85 48.33 26 63
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majority of these significant changes occurred in the
TTO and CHX groups. Paired t tests confirmed that
the use of TTO-containing gel resulted in the greatest
change in PBI for all data sets during weeks 0-4 and 
0-8. This occurred in 10 time periods out of 15 (three
time periods, i.e., weeks 0-4, 4-8 and 0-8 for five data
sets). Except for lingual surfaces, all of these results
were statistically significant. The group that used a
CHX-containing gel had five time periods with the
greatest change, but none were statistically significant
(Fig 1). The CHX group had the greatest change in GI
in many data sets (eight time periods). Of these, seven
were statistically significant. The TTO group was next
with six time periods with the greatest change, of these
five were statistically significant (Fig 1).
No significant changes were observed in PSS.
However, the TTO group was the only group to show
an increase in plaque scores for weeks 0-4 and 0-8. The
CHX group had the greatest reduction in plaque scores
in many data sets (7), the placebo was next (6), and the
TTO group had the least (1).
DISCUSSION
Within the limitations of the study, it was apparent
that TTO-containing gel decreased the level of gingival
Fig 1. Mean changes in PBI of all teeth, buccal/lingual and anterior/posterior data sets.
( denotes statistically significant intragroup changes between time periods 0-4, 4-8 and 0-8 weeks).

































inflammation more so than did the positive and
negative controls. Of particular interest, the
improvements in PBI in the TTO group were not
accompanied by reduced plaque scores.
Although the TTO group did not exhibit mean
changes greater than one unit, it did approach it for
several data sets. For example, it reached a mean value
of 0.75 for buccal surfaces (average change weeks 0-4),
three times that achieved by the CHX group (0.26) and
over twice that of the PLB group (0.33). The 95 per
cent confidence intervals for buccal surfaces showed a
one unit change (range 0.49-1.01), indicating that
clinically measurable changes occurred at buccal sites
in the TTO group.
The TTO group had the largest number of improved
sites for the following data sets: all teeth, posterior
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Fig 2. Changes in GI of all teeth, buccal/lingual and anterior/posterior data sets.
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teeth, anterior teeth and buccal surfaces. All data sets
(excluding the anterior teeth) had statistically
significant improvements for the 0-4 week time period.
The buccal surfaces showed the largest improvements
in PBI. The changes observed in PBI indicated that TTO
reduced existing gingivitis in subjects to a greater extent
than occurred in the other groups.
No significant differences between group means or
mean changes were detected in the ANOVA tests,
indicating that the responses were similar or small,
depending on the data set. The results are similar to
those of most CHX gel studies21-23 but the magnitude of
changes reported by these authors was greater than
observed in the current study. A likely explanation is
that subjects had a scale and clean at baseline in the
studies referred to. The changes reported were
therefore due to a combined effect of mechanical
treatment and CHX gel. The finding in this study that
the TTO group and the CHX groups had decreased PBI
and GI scores may point to a clinically relevant
therapeutic effect because oral hygiene practices were
average to poor and subjects had considerable deposits
of supragingival/subgingival plaque and calculus
throughout the study.
There is no ‘gold standard’ index for assessing the
degree of gingivitis or the treatment effects of various
agents or treatment methods. Since the GI has been the
most widely used index in studies investigating oral
hygiene products, it was included in this study to
permit comparison between studies. However, there are
significant limitations inherent in the GI that receive
scant attention in the periodontal literature. GI has
fewer scoring criteria than PBI; it therefore provides
less information and is less sensitive than the PBI to
smaller changes in gingival inflammation. The GI was
formulated when the science of periodontology was in
its infancy. At the time, it was thought that colour
changes in the gingival tissues preceded the
development of BOP, whereas subsequent research has
shown the reverse to be the case.24,25 Gingival colour
change is not necessarily an accurate indicator of
gingival inflammation, as incipient gingival
inflammatory lesions have BOP but do not necessarily
have altered colour. Also mucocutaneous lesions
(erosive lichen planus, pemphigus, etc.) of the gingival
tissues can be a confounding factor when using colour
changes in periodontal indices.
If the current study were to be extended, the
inclusion of a clinical measure of gingival inflammation
that increased objectivity would be warranted. This
may include an assessment of subgingival pocket
temperatures26 or cytokine measurements (e.g., IL-1, IL-
6, IL-8).27
Information gathered from the current trial and the
limited literature indicates that TTO’s antibacterial
effects, although potent in vitro, do not translate to
inhibition of plaque formation in vivo. Few changes
occurred in the PSS parameter, including in the CHX
group; no changes in PSS reached statistical
significance. There are only two published studies
assessing TTO’s effects on oral bacteria and on plaque
formation in vivo. The response in PSS of the TTO
group in the current trial was similar to other studies
that have investigated TTO as an oral antibacterial
agent.28 However, direct comparison of the results is not
possible because the TTO vehicle in those
investigations was a mouthwash rather than a gel and
the studies’ protocols were very different. A TTO
containing mouthwash was effective in decreasing
salivary bacterial counts for approximately 1/2 an hour.
This decrease was comparable to the CHX control, but
after six hours, salivary bacterial levels nearly returned
to normal whereas the activity of CHX persisted.
Similar results were seen in a clinical trial of TTO
mouthwash,28 in a study (crossover design) with a
washout period of three days in eight subjects. In the
first week, water was used as a mouthwash in the
absence of oral hygiene for four days, CHX
mouthwash was used in the second week and TTO
mouthwash in the last week. Plaque index and areas
were scored, as was vital fluorescence to detect vital
bacterial colonies. The TTO containing mouthwash
had no effect on the quantity or quality of
supragingival plaque.
The CHX group’s plaque scores in this study did not
change significantly. However, the CHX group had the
greatest mean changes compared to the other groups.
This is contrary to the findings of clinical studies
investigating CHX gel, although clinical effects of CHX
gel on plaque have been variable depending on the
frequency of use, concentration used and whether or
not subjects were treated or untreated at the beginning
of the study making comparison between studies
difficult.21-23,29,30 Consistent with the present findings, the
majority of treatment effects occurred early in the
observation periods (0-4 weeks), possibly indicating
decreased compliance later in the studies or that the end
point of treatment effects had been reached, i.e.,
improvements in clinical parameters reached a plateau
after which no further improvement was possible.21,22
Poor compliance with gel use may have contributed
to the limited changes seen in PSS, particularly in
relation to the CHX group. An indirect indicator of
compliance may have been the time taken by subjects to
use the gel over four weeks. The use of gel varied
greatly. The majority of subjects claimed that the
amount of gel supplied was sufficient for four weeks,
with little gel remaining. A few subjects reported that
they had a lot of gel remaining after four weeks,
possibly indicating poorer compliance.
Subjects in this study had pre-existing plaque and
supragingival/subgingival calculus deposits that made
effective oral hygiene difficult and probably facilitated
plaque growth. Using disclosing solution on teeth with
significant calculus deposits would result in staining
irrespective of plaque formation, confounding plaque
measurements. This would have affected all groups’
measurements.
Possible periodontal applications of TTO gel
Since decreased gingival inflammation occurred in
subjects who used TTO without a concomitant
decrease in plaque scores, its mechanism of activity
could have been anti-inflammatory rather than
antibacterial. The components of TTO are known to
decrease inflammation in in vitro and in vivo
settings.2,3,6,7 For example, subjects who were
administered Soledum® (containing 1,8-cineole)
showed a significant decrease in the production of
LBT4 and PGE2 in isolated monocytes.
2 1,8-cineole has
also been shown to significantly inhibit in vitro
cytokine production (TNF-a, IL-1b) from LPS
stimulated monocytes.3 Similar in vitro effects were
shown on monocytes by terpinen-4-ol.6,7
The components of TTO are known to have
lipophilic properties which facilitate its diffusion
through epithelium.5 If TTO is readily absorbed after
topical application into the gingival tissues and has
anti-inflammatory properties once it has entered the
connective tissues, it would be a unique, non-toxic
agent that would be a useful addition to the current
range of chemotherapeutic periodontal treatment
options.
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